Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 10/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 12/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 12/20 | 0.59 |
| ▸ | LMNA | P02545 | 11/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.59 |
| ▸ | TSHR | P16473 | 9/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 8/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 8/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4069915 | 0.85 | EGFR (0.72) | EGFRMAPK1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3932470 | 0.82 | EGFR (0.59) | EGFRMAPK1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13960275 | 0.82 | EGFR (0.62) | EGFRMAPK1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL24466944 | 0.81 | EGFR (0.72) | EGFRALDH1A1HPGDKDM4EFLT1 | |
| SCHEMBL5380842 | 0.80 | CYP1A2 (0.59) | EGFRMAPK1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4066184 | 0.78 | FLT1 (0.56) | EGFRALDH1A1KDM4EFLT1TUBB4A | |
| SCHEMBL4071062 | 0.78 | TYK2 (0.62) | EGFRLMNAFLT1MAPTMEN1 | |
| SCHEMBL3936767 | 0.78 | NPR1 (0.61) | EGFRMAPK1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL28401452 | 0.77 | EGFR (0.46) | EGFRMAPK1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7126923 | 0.77 | EGFR (0.73) | EGFRMAPK1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | claimed |
| EP-2014663-A1 | Thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2009-01-14 | — | — | EP | claimed |
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| EP-2014663-A1 | Thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | EGFR 875/4885MAPK1 1719/4885CYP1A2 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.